 Beam Therapeutics Inc NASDAQ: BEAM reported a wider Q1 net loss of 201.6 million compared to 31.7 million a year ago, on higher RD costs of 190.1 million, up from 21.5 million in Q1 2020. It includes 155 million of expense related to in-process research and development acquired from Guide Therapeutics Inc in February this year. 